List of Excipients in Branded Drug BALANCED SALT

Generic Drugs Containing BALANCED SALT

Company	Ingredient	NDC	Excipient
B Braun Medical Inc	sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium acetate, and sodium citrate	0264-1945	HYDROCHLORIC ACID
B Braun Medical Inc	sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium acetate, and sodium citrate	0264-1945	SODIUM HYDROXIDE
B Braun Medical Inc	sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium acetate, and sodium citrate	0264-1945	WATER
B Braun Medical Inc	sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium acetate, and sodium citrate	0264-2514	HYDROCHLORIC ACID
B Braun Medical Inc	sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium acetate, and sodium citrate	0264-2514	SODIUM HYDROXIDE
B Braun Medical Inc	sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium acetate, and sodium citrate	0264-2514	WATER

What are the Most Frequently-Used Excipients in BALANCED SALT?

# Of NDCs	Excipient
4	HYDROCHLORIC ACID
4	SODIUM HYDROXIDE
4	WATER

Balanced Salt Excipient Strategy and Commercial Opportunities in Ophthalmic Irrigation

Last updated: August 12, 2026

Balanced Salt Solution, commonly marketed as BSS by Alcon, is an ophthalmic irrigation product used during ocular surgery. Its commercial value comes from sterile manufacturing, validated packaging, operating-room supply reliability, and surgeon preference rather than from active-ingredient exclusivity. The strongest opportunities are private-label supply, preservative-free delivery systems, regional manufacturing, and differentiated formulations for cataract, vitreoretinal, corneal, and refractive procedures.

What is Balanced Salt Solution and how is it regulated?

Balanced Salt Solution is a sterile, isotonic aqueous ophthalmic irrigation product. It is used to irrigate and maintain the anterior chamber during ophthalmic surgery and to hydrate exposed ocular tissue.

The product is regulated as a prescription ophthalmic drug in the United States. Alcon’s BSS product is associated with FDA-approved labeling under the BSS product family. BSS PLUS is a related product that contains additional components, including glutathione, and is used in ophthalmic surgical procedures. Product-specific labeling controls the approved composition, indications, storage, packaging, and administration requirements.[1]

Typical BSS composition

A conventional BSS formulation generally contains:

Component	Functional role
Sodium chloride	Primary tonicity contributor
Potassium chloride	Supports ionic balance
Calcium chloride dihydrate	Provides calcium ions
Magnesium chloride hexahydrate	Provides magnesium ions
Sodium acetate trihydrate	Buffering and ionic balance
Sodium citrate dihydrate	Buffering and calcium-complexing contribution
Hydrochloric acid or sodium hydroxide	pH adjustment
Water for Injection	Solvent

BSS PLUS adds reduced glutathione and uses bicarbonate-related buffering requirements. The exact composition, concentration ranges, manufacturing controls, and labeling should be taken from the applicable FDA-approved package insert rather than inferred from generic electrolyte formulations.[1]

What excipients are most important in Balanced Salt formulations?

The excipient strategy is based on physiologic compatibility, chemical stability, sterility, particulate control, and low risk of ocular toxicity. Unlike an oral tablet, the formulation has little room for conventional excipient differentiation.

Tonicity and ionic balance

Sodium chloride establishes much of the solution’s osmolality. Potassium, calcium, and magnesium salts replicate key extracellular ions and support compatibility with ocular tissues during surgery.

Commercial developers should control:

• Osmolality and osmolality drift over shelf life
• Individual ion concentrations
• Total ionic strength
• Precipitation risk
• pH after terminal sterilization
• Container-material interactions

Calcium and magnesium create particular manufacturing challenges because they can interact with phosphate, carbonate, citrate, and other anions. The formulation should avoid precipitation under expected storage and administration conditions.

Buffer system

Acetate, citrate, bicarbonate, and pH-adjusting agents influence pH stability. A developer must balance buffering capacity against:

• Carbon dioxide exchange
• Container closure permeability
• Heat exposure
• Headspace composition
• pH change after opening
• Compatibility with surgical instruments and ophthalmic tissues

Bicarbonate-containing systems may offer physiologic positioning but can create greater packaging and stability demands than a simpler acetate-citrate system.

Antioxidant strategy

BSS PLUS uses glutathione as a formulation component. Glutathione can support the intended product performance but introduces oxidation, assay, and packaging considerations. Developers should evaluate:

• Reduced versus oxidized glutathione
• Oxygen exposure during compounding and filling
• Headspace oxygen
• Light sensitivity
• Metal-ion catalysis
• Container closure oxygen transmission
• Stability-indicating analytical methods

Antioxidant addition is not automatically advantageous. It can increase raw-material qualification requirements, analytical burden, and batch-release complexity.

Water quality and particulate control

Water for Injection is a critical material. The product must meet applicable requirements for sterility, bacterial endotoxins, visible particles, subvisible particles, and container integrity. Ophthalmic irrigation products face high scrutiny because they are introduced directly into the surgical field.

The commercial differentiation is often in process capability rather than in the ingredient list. Important controls include:

• High-purity water systems
• Validated mixing order
• Controlled addition of calcium and magnesium salts
• Bioburden limits before sterilization
• Terminal sterilization or validated aseptic processing
• Filter integrity, where applicable
• Container closure integrity
• Particulate inspection
• Extractables and leachables testing

What formulations are protected by Balanced Salt intellectual property?

The conventional BSS formulation is unlikely to support a broad, durable composition patent position on its own. The main defensible assets are more likely to involve manufacturing processes, packaging, stability, container systems, specialized surgical uses, or modified formulations.

Potentially protectable formulation features

A developer could pursue patent protection for:

1. A defined electrolyte ratio that improves corneal endothelial-cell preservation.
2. A glutathione-containing formulation with improved oxidative stability.
3. A low-particulate formulation produced through a controlled order of addition.
4. A formulation with improved stability after opening or repeated surgical access.
5. A container closure that limits oxygen or carbon dioxide ingress.
6. A ready-to-use product with a validated shelf life at room temperature.
7. A dual-chamber or point-of-use mixing system.
8. A formulation optimized for a specific ophthalmic procedure.
9. A low-calcium or calcium-free product for a defined surgical application.
10. A product with compatibility advantages for intraocular lenses or surgical instruments.

The patentability threshold is higher where the formulation simply reproduces known physiologic electrolytes. Stronger claims require reproducible technical effects, such as improved endothelial-cell viability, reduced precipitation, longer stability, or improved surgical handling.

How strong is the patent estate for Balanced Salt?

The commercial patent estate is likely weaker than the regulatory and manufacturing barriers. BSS is a mature, aqueous, multicomponent product with ingredients that are generally well known. Patent strength therefore depends on claim scope and remaining term for any formulation or packaging patents, not on the existence of a proprietary active pharmaceutical ingredient.

Asset category	Likely commercial importance	Patent strength
Basic electrolyte composition	High	Low to moderate
Glutathione-containing formulation	Moderate to high	Moderate if supported by stability data
Sterile manufacturing process	High	Moderate
Container closure and packaging	High	Moderate
Surgical method-of-use claims	Moderate	Variable
Trademark and brand recognition	High	Not a patent right
Regulatory dossier and quality system	Very high	Non-patent barrier
Supply contracts and hospital formulary access	Very high	Contractual barrier

A freedom-to-operate review should cover U.S. patents, pending applications, continuation practice, European patents, national filings in major ophthalmic markets, and third-party patents covering terminal sterilization, oxygen-controlled packaging, and ocular surgery applications.

What is the Orange Book status of Balanced Salt?

The Orange Book is relevant only if the product is listed as an approved drug product subject to the applicable FDA drug-listing framework. BSS products are not comparable to small-molecule drugs with a single active ingredient and a dense Orange Book patent estate.

The principal regulatory questions are:

• Whether the specific BSS product has an active FDA approval.
• Whether the reference product has listed patents.
• Whether any listed patents cover the formulation, container, method of use, or other approved features.
• Whether an abbreviated new drug application pathway is available.
• Whether the proposed product is sufficiently equivalent to support an ANDA.
• Whether the FDA would require a 505(b)(2) application because of formulation, presentation, or clinical differences.

FDA Drugs@FDA and the current Orange Book should be checked for the specific product, dosage form, application number, and sponsor before making a Paragraph IV or launch assessment.[2,3]

When does Balanced Salt lose exclusivity?

Balanced Salt does not have a single commercial exclusivity date comparable to a patented small-molecule medicine. Any exclusivity analysis must separate four categories:

Exclusivity or barrier	Relevance to BSS
New chemical entity exclusivity	Generally not relevant
New formulation or 3-year exclusivity	Possible if a qualifying approval supports it
Orphan-drug exclusivity	Not relevant to ordinary ophthalmic irrigation
Patent exclusivity	Depends on issued claims and expiration dates
Regulatory and quality-system barriers	Often more important than statutory exclusivity
Trademark rights	Protect the BSS brand, not the formulation itself

A competing manufacturer may enter after satisfying FDA requirements even if the incumbent retains trademark rights. The competitor cannot market its product as BSS or imply that it is the Alcon product, but it may use a separate proprietary name or a generic description permitted by FDA labeling.

Are Paragraph IV challenges likely for Balanced Salt?

A Paragraph IV challenge is possible only if the target product has relevant listed patents and the proposed ANDA applicant relies on the reference listed drug. The practical value of a Paragraph IV filing depends on the number, scope, and remaining term of listed patents.

For a mature sterile irrigation product, the greater risk may be regulatory rather than litigation-related. An applicant could face questions involving:

• Formulation sameness
• pH and osmolality
• Sterility assurance
• Container closure integrity
• Particulate profile
• Stability data
• Manufacturing-site inspection
• Device or administration compatibility
• Labeling differences

A patent challenge becomes commercially attractive when the reference product has high hospital utilization, limited qualified suppliers, and a concentrated supply base. It becomes less attractive when the product has low margins, significant sterile manufacturing costs, and limited ability to substitute within hospital purchasing systems.

What patent litigation affects Balanced Salt?

There is no well-known, industry-defining patent litigation pattern comparable to the litigation surrounding major oncology, immunology, or diabetes products. Litigation risk is more likely to arise from:

• ANDA patent litigation involving a listed formulation or packaging patent
• Trade-secret disputes involving sterile manufacturing
• Trademark disputes involving the BSS name
• Contract disputes with hospitals, distributors, or contract manufacturers
• Product-liability claims related to contamination, particles, or sterility failures
• Patent disputes over specialty ophthalmic formulations

The absence of major public litigation does not establish freedom to operate. Mature ophthalmic products can have unpublished commercial know-how, continuation applications, foreign rights, or patent claims that are not central to the brand’s public positioning.

What generic entry risks exist for Balanced Salt?

Generic entry risk is moderate from a technical perspective and high from a commercial execution perspective.

Technical entry barriers

A competitor must demonstrate consistent performance across:

• Assay of every ionic component
• pH
• Osmolality
• Sterility
• Endotoxin level
• Particulate matter
• Stability
• Container closure integrity
• Shipping conditions
• Labeling and administration

A sterile aqueous product can appear simple but is difficult to manufacture economically at reliable scale. Small deviations in mixing, sterilization, packaging, or storage can produce precipitation, pH drift, particulate contamination, or shortened shelf life.

Commercial entry barriers

Hospitals and ambulatory surgery centers often prioritize:

• Reliable supply during procedure scheduling
• Low recall risk
• Vendor qualification
• Consistent bottle or bag design
• Surgical staff familiarity
• Distributor availability
• Contract pricing
• Product continuity

A new supplier may need to discount materially to displace an established product. The product’s low unit price can also limit the return on expensive clinical, regulatory, and manufacturing work.

What commercial opportunities exist in Balanced Salt excipients?

The largest opportunities are adjacent to the base formulation.

Private-label and contract manufacturing

Regional ophthalmic manufacturers can offer hospital systems, distributors, and surgical networks private-label sterile irrigation products. The value proposition is supply redundancy, lower logistics cost, and procurement flexibility.

The most attractive customers are:

• Large ambulatory surgery networks
• Regional hospital systems
• Ophthalmology-focused distributors
• International tender purchasers
• Surgical-kit assemblers
• Specialty pharmaceutical companies without sterile fill-finish capacity

Packaging differentiation

Packaging can create practical value even when the solution is compositionally similar. Potential formats include:

• Single-use bottles
• Flexible bags
• Smaller-volume surgical presentations
• Low-overfill containers
• Dual-chamber systems
• Oxygen-limited packaging
• Lightweight containers for international distribution
• Integrated spike or port designs

Packaging must be assessed under FDA container-closure, extractables, leachables, and sterility requirements. A packaging patent may be more commercially useful than a narrow electrolyte-composition patent if it solves a real operating-room problem.

Procedure-specific products

A supplier could develop products positioned for:

• Cataract surgery
• Vitrectomy
• Corneal transplantation
• Refractive surgery
• Glaucoma surgery
• Retinal procedures
• Organ or tissue preservation applications

Procedure-specific positioning must be supported by labeling, technical data, or clinical evidence. A marketing claim that exceeds the approved indication can create FDA and enforcement risk.

Excipient and raw-material supply

Specialty suppliers can compete in:

• Pharmaceutical-grade glutathione
• High-purity calcium and magnesium salts
• Low-endotoxin sodium salts
• Sterile water systems
• Oxygen-control packaging
• Container closure systems
• Stability-indicating analytical methods

The most defensible position is a qualified, validated supply chain with documented lot consistency. Commodity pricing alone is unlikely to provide durable differentiation.

How does Balanced Salt compare with competing ophthalmic irrigation products?

Product category	Primary use	Differentiation	Entry difficulty
Conventional BSS	General ophthalmic irrigation	Established electrolyte balance and brand	Moderate
BSS PLUS-type product	Ophthalmic surgery with glutathione-containing formulation	Antioxidant and formulation profile	Moderate to high
Lactated Ringer’s solution	General fluid replacement and some procedural uses	Different electrolyte and lactate profile	Low as a general fluid, higher for ophthalmic substitution
Custom intraoperative irrigants	Specialized procedures	Procedure-specific composition	High
Ocular viscoelastic products	Chamber maintenance and tissue protection	Viscosity and surgical manipulation	High
Tissue-preservation solutions	Corneal or organ preservation	Preservation performance and validated use	High

General parenteral fluids are not automatically interchangeable with ophthalmic irrigation products. Differences in composition, pH, osmolality, calcium content, labeling, packaging, and sterility claims can prevent direct substitution.

What licensing deals are relevant to Balanced Salt?

The most logical licensing targets are not active ingredients. They are:

• Sterile manufacturing technology
• Container closure technology
• Oxygen-control systems
• Glutathione stabilization methods
• Hospital distribution rights
• Regional trademarks
• Procedure-specific formulation know-how
• Contract manufacturing capacity

A licensing transaction should allocate responsibility for FDA submissions, post-approval changes, pharmacovigilance, recalls, supply interruptions, process validation, and product liability. Because BSS is a relatively low-cost product, royalty economics may favor a fixed technology fee, minimum annual volumes, or supply-margin arrangements over a high percentage royalty.

What FDA regulatory pathway is most practical for a new Balanced Salt product?

The pathway depends on the proposed product’s relationship to the reference product.

Development scenario	Likely pathway
Same formulation, same route, same dosage form, comparable labeling	ANDA may be considered
Modified electrolyte balance or added antioxidant	505(b)(2) may be more suitable
New clinical claim or materially different use	NDA or 505(b)(2), depending on the product
Product made outside the United States	FDA drug application plus establishment and import compliance
Hospital compounding without commercial distribution	Separate compounding framework may apply, but it is not equivalent to commercial approval

The principal development cost is usually driven by sterile manufacturing validation, analytical method qualification, stability studies, container closure testing, and regulatory documentation. Clinical studies may be limited for a truly equivalent product but could become necessary for a materially different formulation or claim.

What is the revenue exposure and competitive outlook?

BSS revenue is exposed to procedure volumes, cataract surgery growth, hospital purchasing contracts, distributor concentration, and supply interruptions. The product’s unit economics are generally less attractive than those of premium ophthalmic drugs, but recurring use and high procedural frequency can support meaningful aggregate revenue.

The incumbent’s advantages are likely to include:

• Brand recognition among ophthalmic surgeons
• Existing hospital contracts
• Established global distribution
• Validated sterile manufacturing
• Product familiarity
• Existing regulatory infrastructure

The main threats are:

• Price-based procurement
• Hospital demand for dual sourcing
• Manufacturing outages
• Private-label substitution
• Regional competitors
• Formulation innovation in specialty surgery
• Distributor consolidation

A credible entrant should target supply reliability and procurement economics rather than attempt to compete only through a new excipient combination.

Key Takeaways

• Balanced Salt Solution is a mature sterile ophthalmic irrigation product, not a conventional active-ingredient patent opportunity.
• Excipient value centers on ionic balance, pH, osmolality, antioxidant stability, sterility, and particulate control.
• Basic electrolyte-composition claims are likely to face prior-art and obviousness pressure.
• Stronger opportunities may exist in packaging, oxygen control, manufacturing process, specialty formulations, and procedure-specific use.
• FDA approval, sterile manufacturing, hospital qualification, and distribution access are more important commercial barriers than statutory exclusivity.
• Paragraph IV risk depends on product-specific Orange Book listings and remaining patent term.
• Biosimilar risk is not applicable because BSS is a chemically defined aqueous drug product, not a biologic.
• The most viable commercial strategies are private-label supply, regional contract manufacturing, dual-source procurement, and differentiated packaging.
• Any investment or licensing review should analyze the exact FDA application, approved composition, current Orange Book record, patent family, and target jurisdiction.

FAQs

Is Balanced Salt Solution a generic drug or a branded ophthalmic product?

Both concepts can apply. BSS is a branded product family associated with Alcon, while competing manufacturers may seek approval for equivalent or comparable ophthalmic irrigation products under separate proprietary names.

Can Lactated Ringer’s replace Balanced Salt Solution during eye surgery?

Not automatically. The products have different compositions, labeling, and regulatory status. Surgical substitution requires clinical and regulatory support for the intended ophthalmic use.

Does glutathione create a patentable advantage in BSS PLUS-type products?

It can support patent protection only when the claimed formulation produces a non-obvious technical benefit, such as improved stability, reduced oxidation, or improved tissue compatibility. Glutathione alone may not establish a strong composition patent.

Are Balanced Salt products subject to biosimilar competition?

No. Biosimilar regulation applies to biological products. Balanced Salt is a chemically defined sterile aqueous formulation, so competition would arise through generic, 505(b)(2), or other applicable drug pathways.

What is the best entry strategy for a new Balanced Salt manufacturer?

The strongest strategy is usually a validated equivalent product paired with reliable sterile supply, hospital contracting, regional distribution, and packaging or logistics improvements. A novel excipient combination without a clear clinical or operational benefit is less likely to create durable value.

References

1. U.S. Food and Drug Administration. (n.d.). BSS and BSS PLUS ophthalmic products: Prescribing information. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

4. United States Pharmacopeia. (2024). General chapter <771>: Ophthalmic products. United States Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (2024). Sterile drug products produced by aseptic processing: Current good manufacturing practice. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice

6. U.S. Food and Drug Administration. (2024). Guidance for industry: Container closure systems for packaging human drugs and biologics. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/container-closure-systems-packaging-human-drugs-and-biologics